Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said.
Carmenta gains licensing option for preeclampsia diagnostic tool
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management